文献速递胸部肿瘤消化系统肿瘤泌尿男性生殖肿瘤

FRACTION计划:免疫肿瘤联合治疗快速实时评估的高通量临床筛查平台

The Fast Real-time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) program: innovative, high-throughput clinical screening of immunotherapies.
PubMed 文献 · Eur J Cancer · 2018-10-03

FRACTION是百时美施贵宝设计的II期平台试验,采用主方案与子方案框架及适应性随机设计,在晚期非小细胞肺癌、胃癌和肾细胞癌患者中同时评估多种免疫肿瘤联合方案。主要终点为客观缓解率、中位缓解持续时间和24周无进展生存率,次要终点为安全性与耐受性,并通过治疗前后生物标志物采集识别获益人群。

要点

  • FRACTION为开放标签II期平台试验,采用适应性随机与滚动联合方案设计。
  • 主方案提供整体框架,子方案随时间引入具体免疫联合治疗细节。
  • 主要终点包括ORR、中位DOR和24周PFS率,次要终点为安全性与耐受性。

核心结论

  • FRACTION计划通过针对特定肿瘤的独立研究、采用适应性试验设计和连续入组,可评估多种免疫肿瘤联合方案。

研究设计与样本

  • FRACTION计划由开放标签II期研究组成,采用适应性随机设计和滚动联合方案。
  • 主方案提供整体研究设计框架,随时间引入的子方案提供具体免疫肿瘤联合治疗细节。
  • 患者根据既往免疫治疗经历等特征入组不同研究轨道,进展后可重新随机至其他子方案中的联合方案。

主要发现

  • 主要目标为评估客观缓解率、中位缓解持续时间和24周无进展生存率。
  • 次要目标为研究安全性和耐受性。
  • 治疗前和治疗中的生物标志物采集将有助于识别从每种治疗中获益最多的患者亚群。

临床怎么用

  • 该平台设计可在特定肿瘤患者中高效识别有前景的免疫肿瘤联合方案。
  • 允许进展后重新随机至其他联合方案,并支持生物标志物引导的获益人群识别。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The unprecedented success of immuno-oncology (I-O) agents targeting the cytotoxic T lymphocyte-associated antigen 4 and programmed death-1/programmed death-ligand 1 pathways has stimulated the rapid development of other I-O agents against novel immune targets. Bristol-Myers Squibb has designed a novel phase II platform trial, the Fast Real-time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) Program, to efficiently identify promising combinations for patients with specific malignancies. The concept and study design of the FRACTION Program-currently ongoing in patients with advanced non-small-cell lung cancer (FRACTION-Lung), gastric cancer (FRACTION-Gastric Cancer) and renal cell carcinoma (FRACTION-RCC)-are described. METHODS: The FRACTION Program comprises open-label, phase II studies that use adaptive randomisation designs with rolling combination regimens. Master Protocols provide the overall study design framework, whereas Sub-Protocols introduced over time provide details on specific I-O combination therapies to which patients may be randomised. In a Master Protocol, patients are enrolled into different Study Tracks based on characteristics such as prior I-O therapy experience. Patients who progress may be rerandomised to other combination regimens from any ongoing Sub-Protocol. Primary objectives are to assess objective response rate, median duration of response and progression-free survival rate at 24 weeks; the secondary objective is to investigate safety and tolerability. Biomarker collection before and on treatment will facilitate identification of patient subsets who benefit most from each therapy. CONCLUSIONS: The FRACTION Program allows for the evaluation of multiple I-O combinations through individual studies for specific tumours using an adaptive trial design and continuous enrolment.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Simonsen KL, Fracasso PM, Bernstein SH, et al. The Fast Real-time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) program: innovative, high-throughput clinical screening of immunotherapies. Eur J Cancer. 2018. PMID: 30292142. doi:10.1016/j.ejca.2018.07.127

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。